Vandria SA, established as a biopharmaceutical spin-off from Amazentis SA, was officially incorporated in Switzerland in 2021. The company specializes in the discovery and development of innovative small molecules designed to effectively induce mitophagy for the treatment of age-related and chronic diseases. Vandria is currently in the IND-enabling stage, boasting two lead candidates who have demonstrated highly promising resu...
Vandria SA, established as a biopharmaceutical spin-off from Amazentis SA, was officially incorporated in Switzerland in 2021. The company specializes in the discovery and development of innovative small molecules designed to effectively induce mitophagy for the treatment of age-related and chronic diseases. Vandria is currently in the IND-enabling stage, boasting two lead candidates who have demonstrated highly promising results in both in vitro and in vivo studies. Anticipated to commence in the second quarter of 2024, the first clinical trials mark a significant milestone.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.